" class="no-js "lang="en-US"> David M. Reese - Medtech Alert
Thursday, September 04, 2025
David M. Reese

David M. Reese

About David M. Reese

Dr. David M. Reese is executive vice president, Research and Development. In this role, Dr. Reese oversees Discovery Research, Global Development, Global Regulatory Affairs and Safety, as well as Global Medical. Dr. Reese joined Amgen in 2005 and has served in various leadership roles within the Research and Development organization. This includes most recently serving as Senior Vice President of Translational Sciences and Oncology where he oversaw the translation of Amgen’s medicines from the lab into the clinic and the overall oncology strategy.

Prior to joining Amgen, Dr. Reese was director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a co-founder, president and chief medical officer of Translational Oncology Research International (TORI), a not-for-profit academic clinical research organization.

Dr. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed training in Internal Medicine and Hematology/Oncology at the University of California, Los Angeles (UCLA) School of Medicine, and subsequently served on the faculty at UCLA and the University of California, San Francisco.

Related Story

Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases

October 7 2021

Amgen (NASDAQ: AMGN) and Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company pioneering precision medicines for […]

FDA Approves Repatha ® (evolocumab) in Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia

September 27 2021

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha ® (evolocumab) as an […]

Amgen to Acquire Privately Held Teneobio for $900 Million in Cash With Future Contingent Milestone Payments

July 28 2021

Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a […]

FDA Accepts Amgen's sNDA For Otezla ®

May 6 2021

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for […]